Glenmark Pharma came out with its Q2FY08 results and held a conference call discuss the same and its future outlook. here are the key takeaways.....
It has posted growth of 59% in its consolidated net profit of Rs 75.1 crore for the quarter ended September 2007 as against Rs 40.2 crore in same quarter of last year.
Revenues from the US front end has grown dramatically from USD 13 million in FY 2006 to USD 50 million in FY 2007, a growth of 286% with 13 generics on the market.
It works in more than 80 countries and its over 60% of revenue comes from outside India.
Outlicences GRC-6211 to Eli Lily, to get upfront USD 45 million to get additional USD 215 million in Potential Dvpt & Sales Milestones.
It has no plan to demerge its R&D.
It wish to launch 2 proproetary molecules between 2010 and 2014 through own developement and in-licenced molecules.
